Does Centene Corporation Cover Eliquis?

How Centene Corporation Structures Drug Coverage

Centene Corporation is the largest Medicaid managed-care organization in the United States, operating health plans under multiple brand names across more than 30 states. Its subsidiary brands include Ambetter (Affordable Care Act Marketplace plans), WellCare (Medicare Advantage and Medicaid), Fidelis Care (New York Medicaid and Medicare), and numerous state-specific Medicaid managed-care products.

Each subsidiary maintains its own pharmacy formulary, but Centene's corporate pharmacy and therapeutics (P&T) committee sets baseline coverage recommendations that trickle down to plan-level decisions. Eliquis (apixaban), manufactured by Bristol-Myers Squibb and Pfizer, appears on the majority of these formularies because the American College of Cardiology and American Heart Association guidelines recommend direct oral anticoagulants (DOACs) as first-line therapy for non-valvular atrial fibrillation and venous thromboembolism [1].

The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% versus warfarin (1.27% vs. 1.60% per year; HR 0.79 to 95% CI 0.66-0.95) with a 31% reduction in major bleeding [2]. These outcomes give Centene's formulary committees strong clinical rationale to include the drug.

Formulary Tier Placement Across Centene Plans

Where Eliquis lands on your formulary determines what you pay. Centene plans use a tiered structure that typically includes four to six tiers: Tier 1 (generic), Tier 2 (preferred brand), Tier 3 (non-preferred brand), Tier 4 (specialty), and sometimes Tier 5 (premium specialty).

Across Ambetter Marketplace plans, Eliquis most frequently appears on Tier 3 (preferred brand) with copays ranging from $50 to $95 per fill after deductible. WellCare Medicare Advantage Part D plans generally place it on Tier 3 as well, though some enhanced plans offer Tier 2 placement with lower cost-sharing during the Initial Coverage Phase.

For Centene Medicaid managed-care products, cost-sharing is minimal or zero per federal and state rules. The relevant barrier here is not copay but access: prior authorization requirements, step-therapy protocols, and quantity limits control utilization.

The FDA-approved prescribing information for Eliquis lists three primary indications: stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and DVT/PE prophylaxis after hip or knee replacement surgery [3]. Coverage on Centene plans applies to all FDA-approved indications, though off-label use may require additional documentation.

Prior Authorization and Step-Therapy Requirements

Most Centene plans require prior authorization for Eliquis. The PA criteria typically include confirmation of an FDA-approved indication, documentation that the patient has no contraindications, and in many states, evidence that a lower-cost anticoagulant was tried or considered.

Step therapy is common. Centene's Medicaid plans in states such as Georgia (Peach State Health Plan), Texas (Superior HealthPlan), and Illinois (Meridian Health Plan) often require a trial of warfarin or generic rivaroxaban before approving Eliquis. The step-therapy requirement reflects cost-management priorities: generic rivaroxaban became available in 2023, offering a DOAC alternative at roughly 80% lower cost.

However, the 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation gives apixaban a Class I recommendation, noting its superior bleeding profile compared to rivaroxaban in observational data [4]. A physician can cite this evidence in a prior authorization request to bypass step therapy.

Typical turnaround time for PA decisions on Centene plans is 24-72 hours for standard requests and 24 hours for urgent requests. If denied, members have the right to appeal. An expedited appeal must be decided within 72 hours for Medicaid and 24 hours for Medicare Advantage plans, per CMS guidelines [5].

Cost Breakdown: What You Will Actually Pay

The retail price of Eliquis without insurance averages $594 per month for the standard 5 mg twice-daily regimen (60 tablets). With Centene coverage, your actual out-of-pocket cost depends on several variables.

For Ambetter Marketplace plans, expect to pay between $50 and $150 per 30-day supply after meeting your deductible. Silver-tier plans with cost-sharing reductions (CSR) for members under 200% of the federal poverty level may reduce this to $35-$65.

For WellCare Medicare Part D plans, costs follow the standard Medicare benefit design: after the deductible ($590 in 2026), you pay 25% coinsurance during the Initial Coverage Phase until reaching catastrophic coverage. For Eliquis at $594/month, that translates to approximately $148/month during this phase. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) means total annual Eliquis costs are capped regardless of list price [6].

For Centene Medicaid enrollees, federal rules cap copays at nominal amounts. Most Medicaid members pay $0-$4 per prescription, though access requires meeting PA criteria.

Bristol-Myers Squibb offers a manufacturer copay assistance program that can reduce commercially insured patients' costs to as little as $10 per month. This card works alongside Ambetter and other commercial Centene plans but cannot be applied to government-funded coverage (Medicaid, Medicare, TRICARE).

Comparing Eliquis to Other Covered Anticoagulants on Centene Formularies

Centene formularies list multiple anticoagulant options. Understanding where each falls helps you anticipate coverage barriers.

Warfarin (generic) sits on Tier 1 across all Centene plans at $4-$15 per month. It requires INR monitoring every 2-4 weeks and carries higher intracranial bleeding risk compared to DOACs. The RE-LY trial (N=18,113) and ROCKET AF trial (N=14,264) both used warfarin as the comparator, establishing that DOACs offer better safety profiles for most patients [7][8].

Rivaroxaban (Xarelto/generic) is available as a generic since 2023 and typically falls on Tier 1 or Tier 2 at $15-$45 per month. The ROCKET AF trial showed non-inferiority to warfarin for stroke prevention, though rivaroxaban carries higher GI bleeding rates than apixaban [8].

Apixaban (Eliquis) remains brand-only and sits on Tier 3 at $50-$150 per month with insurance. The ARISTOTLE trial showed superiority to warfarin in both efficacy and safety, and a 2022 retrospective analysis published in the Annals of Internal Medicine (N=581,451) found apixaban associated with lower rates of major bleeding compared to rivaroxaban (HR 0.82 to 95% CI 0.76-0.89) [9].

Edoxaban (Savaysa) appears on some Centene formularies as non-preferred brand (Tier 4) with limited utilization. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated non-inferiority to warfarin [10].

How to Get Eliquis Approved on Your Centene Plan

Getting coverage requires a systematic approach. Start by confirming your specific plan's formulary status for apixaban. Every Centene subsidiary publishes its formulary online, and member services can verify tier placement and PA requirements by phone.

Your prescribing physician must submit a prior authorization request to Centene's pharmacy benefit manager (typically CVS Caremark or IngenioRx, depending on the subsidiary). The request should include the specific diagnosis with ICD-10 code (I48.91 for unspecified atrial fibrillation, I82.40 for DVT), CHA₂DS₂-VASc score for AFib patients, rationale for choosing apixaban over alternatives, and documentation of any contraindications to step-therapy agents.

If the initial PA is denied, request a peer-to-peer review. Your physician speaks directly with Centene's medical director to present clinical justification. The Endocrine Society Clinical Practice Guidelines framework for exception requests (applicable broadly to specialty medication appeals) recommends documenting patient-specific factors such as renal function, bleeding history, and drug interactions that favor one agent over another [11].

For formulary exception requests, include published evidence showing medical necessity. The ARISTOPHANES study (N=321,182), a real-world comparative effectiveness analysis published in Stroke, demonstrated that apixaban had the lowest rates of stroke/SE and major bleeding among all DOACs in clinical practice [12]. This type of evidence strengthens exception requests.

State-by-State Variation in Centene Coverage

Centene operates under different subsidiary names in different states, and coverage details vary by state Medicaid program rules. The variation matters because state Medicaid agencies set preferred drug lists (PDLs) that Centene's managed-care plans must follow.

In California (Health Net), the Medi-Cal PDL includes apixaban with PA. In Texas (Superior HealthPlan), step therapy through warfarin is required for most enrollees. In Florida (WellCare/Staywell), Eliquis is covered with standard PA. In New York (Fidelis Care), the state's PDL includes apixaban as a preferred DOAC.

For Medicare Advantage plans, Centene's WellCare brand operates nationally but plan formularies differ by region. The CMS Medicare Plan Finder allows beneficiaries to verify formulary coverage by entering their zip code and medications [5].

Members enrolled through the ACA Marketplace (Ambetter) can check their plan's Summary of Benefits and Coverage (SBC) document, which lists the drug formulary tier structure and links to the complete formulary search tool on their state-specific Ambetter website.

Quantity Limits and Refill Policies

Centene plans enforce quantity limits aligned with FDA-approved dosing. For the standard 5 mg twice-daily regimen (stroke prevention in AFib, DVT/PE treatment after initial therapy), the limit is 60 tablets per 30 days. For the 2.5 mg twice-daily dose (used in patients meeting at least two of three criteria: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL), the limit is also 60 tablets per 30 days.

For VTE prophylaxis after hip or knee replacement, the approved duration is 12 days (knee) or 35 days (hip) at 2.5 mg twice daily. Centene plans will authorize the corresponding quantity for these time-limited indications.

Early refills are generally blocked until 75-80% of the days' supply has elapsed. For a medication with critical adherence importance like an anticoagulant, physicians can override this with vacation supply or lost medication exceptions.

The American Heart Association's 2023 statement on medication adherence notes that DOAC non-adherence increases stroke risk by 2-3 fold within 30 days of discontinuation [13]. This clinical reality supports exception requests for early refills or 90-day supply authorizations when patients face access barriers.

Alternatives If Coverage Is Denied

If Centene denies Eliquis coverage after exhausting the appeals process, several pathways remain.

Bristol-Myers Squibb's patient assistance program provides free Eliquis to uninsured or underinsured patients meeting income criteria (generally below 300% of the federal poverty level). The program ships medication directly to the patient's home.

Generic rivaroxaban offers a clinically acceptable alternative for most patients. While apixaban demonstrates superior bleeding outcomes in observational data, rivaroxaban provides equivalent stroke prevention and once-daily dosing convenience. Switching requires physician oversight given different pharmacokinetic profiles.

Independent charity foundations (such as the HealthWell Foundation and Patient Access Network Foundation) periodically open copay assistance funds for anticoagulants that apply to Medicare beneficiaries who cannot use manufacturer copay cards.

Finally, some patients benefit from requesting a tier exception rather than a full formulary exception. A tier exception moves the drug from Tier 3 to Tier 2 cost-sharing without requiring a formulary override, and Centene is required by CMS rules to process these requests for Medicare Part D enrollees within 72 hours [5].

Patients with a CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women) who have documented warfarin lability (time in therapeutic range <65%) have the strongest clinical case for apixaban-specific coverage, per ACC/AHA guideline recommendations [4].